Thursday, 15 October 2026European Markets

BAKKAFROST Stock Is 12% Down So Far Today

Loading stream...

(VIANEWS) - Shares of BAKKAFROST (Oslo Børs Benchmark Index_GI: BAKKA.OL) slid by a staggering 12.05% to kr562.00 at 11:22 EST on Monday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is dropping 1.12% to kr1,187.58, after two sequential sessions in a row of losses. This seems, at the moment, an all-around down trend trading session today.

About BAKKAFROST

P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products under the Bakkafrost and Havsbrún brands in North America, Western Europe, Eastern Europe, Asia, and internationally. It operates through four segments: Farming FO; Farming SCT; Value Added Products; and Fishmeal, Oil and Fish Feed. The company is involved in the breeding and on-growing of salmon; harvesting, sale, and distribution of salmon; salmon farming, harvest, filleting, sales, and administration; and production of skinless and boneless portions of salmon. It also produces and sells fishmeal, fish oil, and fish feed. In addition, it engages in production of styrofoam boxes, and biogas and fertilizer; and operates trading of fishes, lumpfish farming business, and freight transportation of goods, as well as produce and sell canned fish products. P/F Bakkafrost was founded in 1968 and is headquartered in Glyvrar, Denmark.

Earnings Per Share

As for profitability, BAKKAFROST has a trailing twelve months EPS of kr36.04.

PE Ratio

BAKKAFROST has a trailing twelve months price to earnings ratio of 15.59. Meaning, the purchaser of the share is investing kr15.59 for every norwegian krone of annual earnings.

Volume

Today's last reported volume for BAKKAFROST is 61253 which is 1.93% above its average volume of 60093.

More news about BAKKAFROST (BAKKA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com